Tumor necrosis factor inhibitors in psoriasis: an update

Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S31-6. doi: 10.12788/j.sder.0066.


Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA). This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.

Keywords: Immunogenicity; TNF; psoriasis treatment; tumor necrosis factor inhibitors.

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Certolizumab Pegol
  • Etanercept
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Polyethylene Glycols / therapeutic use
  • Psoriasis / drug therapy*
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Tumor Necrosis Factor Inhibitors*


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Fab Fragments
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor Inhibitors
  • Polyethylene Glycols
  • golimumab
  • Infliximab
  • Adalimumab
  • Etanercept
  • Certolizumab Pegol